Neurological complications of vaccination with outer surface protein A (OspA)

International Journal of Risk and Safety in Medicine

Volumn 23, Issue 2, 2011, Pages 89-96

  Marks, Donald H ^a  

^a Cooper Green Mercy Hospital ^*  (United States)

Author keywords

Lyme disease vaccine; neurologic adverse events; OspA; outer surface protein A

Indexed keywords

CHICKENPOX VACCINE; FREUND ADJUVANT; HEPATITIS B VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LYME DISEASE VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; OUTER SURFACE PROTEIN A; PERTUSSIS VACCINE; RABIES VACCINE; RECOMBINANT PROTEIN; TETANUS TOXOID; THIOMERSAL;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ARTICLE; ASEPTIC MENINGITIS; AUTISM; BELL PALSY; BORRELIA; BRAIN ISCHEMIA; CEREBELLAR ATAXIA; COGNITIVE DEFECT; DEMYELINATING DISEASE; DEMYELINATION; DRUG FATALITY; ENCEPHALITIS; GIANT CELL ARTERITIS; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; INCIDENCE; MENINGOENCEPHALITIS; MULTIPLE SCLEROSIS; MUSCLE HYPOTONIA; MYELITIS; NEUROLOGICAL COMPLICATION; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUROTOXICITY; OPTIC NEURITIS; PARESTHESIA; POLIOMYELITIS; POLYNEUROPATHY; SEIZURE; TRANSIENT ISCHEMIC ATTACK; VACCINATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; BRAIN ISCHEMIA; DEMYELINATING DISEASES; FEMALE; HUMANS; LIPOPROTEINS; LYME DISEASE; MALE; MIDDLE AGED; NERVOUS SYSTEM; OPTIC NEURITIS; RISK ASSESSMENT; UNITED STATES; VACCINATION; VACCINES, SYNTHETIC;

EID: 80051988048     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2011-0527     Document Type: Article

References (44)

1. A.C. Steere, Lyme disease, N Engl J Med 345 (2001), 115-125.
2. G.P. Wormser, Clinical practice. Early Lyme disease, N Engl J Med 354 (2006), 2794-2801.
3. X.F. Yang, U. Pal, S.M. Alani, E. Fikrig and M.V. Norgard, Essential role for OspA/B in the life cycle of the Lyme disease spirochete, J Exp Med 199(5) (1 March 2004), 641-648.
4. P.K. Coyle, J.L. Goodman, L.B. Krupp, et al., Lyme Disease: Continuum: Lifelong Learning in Neurology, Vol. 5. No. 4. Part A. Lippincott Williams & Wilkins, Philadelphia, August 1999.
5. P. Oschmann, W. Dorndorf, C. Hornig, C. Schafer, H.J. Wellensiek and K.W. Pflughaupt, Stages and syndromes of neuroborreliosis, J Neurol 245 (1998), 262-272.
6. W.T. Thanassi and R.T. Schoen, The Lyme disease vaccine: Conception, development, and implementation, Ann Intern Med 132(8) (18 Apr 2000), 661-668.
7. M.S. Hayney, M.M. Grunske and L.E. Boh, Lyme disease prevention and vaccine prophylaxis, Ann Pharmacother 33(6) (June 1999), 723-729.
8. J.F. Bale Jr, Neurologic complications of immunization, J Child Neurol 19(6) (June 2004), 405-412.
9. O. Bolukbasi and M. Ozmenoglu, Acute disseminated encephalomyelitis associated with tetanus vaccination, Eur Neurol 41(4) (1999), 231-232.
10. K. Dieckhofer, R. Scholl, R. Wolf, et al., Neurologic disorders following tetanus vaccination. A case report, Med Welt 29(44) (3 Nov 1978), 1710-1712. German. No abstract available. PMID: 713792; UI: 79052412.
11. G.M. Fenichel, Neurologic complications of tetanus toxoid, Arch Neurol 40(6) (June 1983), 390.
12. G.M. Fenichel, Assessment: Neurologic risk of immunization: Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. American academy of neurology, St. Paul, MN, Neurology 52(8) (12 May 1999), 1546-1552.
13. M.R. Geier, D.A. Geier and A.C. Zahalsky, Influenza vaccination and Guillain Barré Syndromes, Clinical Immunology 107 (2003), 116-121.
14. I. Grotto, Y. Mandel, M. Ephros, I. Ashkenazi and J. Shemer, Major adverse reactions to yeast-derived hepatitis B vaccines-a review, Vaccine 16(4) (Feb 1998), 329-334. Comment in: Ann Intern Med 134(12) (19 June 2001), 1155.
15. N.A. Halsey, P. Duclos, P. Van Damme and H. Margolis, Hepatitis B vaccine and central nervous system demyelinating diseases. Viral hepatitis prevention board, Pediatr Infect Dis J 18(1) (Jan 1999), 23-24.
16. L.S. Label and D.H. Batts, Transverse myelitis caused by duck embryo rabies vaccine, Arch Neurol 39(7) (July 1982), 426-430.
17. K. Lapphra, L. Huh and D.W. Scheifele, Adverse neurological reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination, Pediatr Infect Dis J (3 Aug 2010). [Epub ahead of print]
18. P.E. Pantazopoulos, Perceptive deafness following prophylactic use of tetanus anittoxin, Laryngoscope 75 (Dec 1965), 1832-1836.
19. G. Paradiso, F. Micheli, M. Fernandez Pardal and I. Casas Parera, Multifocal demyelinating neuropathy after tetanus vaccine, Medicina (B Aires) 50(1) (1990), 52-54. Spanish.
20. S. Piyasirisilp and T. Hemachudha, Neurological adverse events associated with vaccination, Curr Opin Neurol 15(3) (June 2002), 333-338.
21. J.D. Pollard and G. Selby, Relapsing neuropathy due to tetanus toxoid, Journal of the Neurological Sciences 37 (1978), 113-125.
22. S.J. Read, G.J. Schapel and M.P. Pender, Acute transverse myelitis after tetanus toxoid vaccination, Lancet 339(8801) (2 May 1992), 1111-1112.
23. J.C. Reijneveld, M.J. Taphoom, T.U. Hoogenraad and J. van Gijn, Severe but transient parkinsonism after tetanus vaccination, J Neurol Neurosurg Psychiatry 63(2) (Aug 1997), 258.
24. D. Sander, C.W. Scholz, P. Eiben, J. Klingelhofer, et al., Postvaccinal plexus neuropathy following vaccination against tick-borne encephalitis and tetanus in a competitive athlete, Clin Investig 72(5) (May 1994), 399. No abstract available. PMID: 8086776; UI: 94369223.
25. C.S. Tornatore and J.R. Richert, CNS demyelination associated with diploid cell rabies vaccine [letter], Lancet 335(8701) (2 June 1990), 1346-1347.
26. D.H. Marks, Evaluation of medical causation, In: Drug Injury: Liability, Analysis and Prevention, 2nd edition, Chapter 10, J.T. O'Donnell ed., L&J Publications, Tucson, AZ, 2005.
27. M.G. Cusi, S. Bianchi, L. Santini, D Donati, M. Valassina, P.E.Valensin, L. Cioe, R. Mazzocchio, et al., Peripheral neuropathy associated with anti-myelin basic protein antibodies in a woman vaccinated with rubella virus vaccine, J Neurovirol 5(2) (Apr 1999), 209-214.
28. L. Herroelen, J. de Keyser and G. Ebinger, Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine, Lancet 338(8776) (9 Nov 1991), 1174-1175.
29. E.S. Hurwitz, L.B. Schonberger and D.B. Nelson, Holman. Guillain RC-Barré Syndrome and the 1978-1979 influenza vaccine, NEJM 26(304) (1981), 1558-1561.
30. T.J. John and D. Mathai, Acute inflammatory demyelinating polyradiculoneuropathy following antirabies vaccine, J Assoc Physicians India 44(11) (Nov 1996), 845-846.
31. F. Karaali-Savrun, A. Altintas, S. Saip and A. Siva, Hepatitis B vaccine related-myelitis? Eur J Neurol 8(6) (Nov 2001), 711-715.
32. B. Maier, M. Molinger, A.P. Cope, L. Fugger, J. Schneider-Mergener, G. Sonderstrup, et al., Multiple cross-reactive self ligands for Borrelia burgdorferi-specific HLA-DR4-restricted T cells, Eur J Immunol 30 (2000), 448-457.
33. D.M. Gross, T. Forsthuber, M. Tary-Lehmann, C. Etling, K. Ito, Z.A. Nagy, J.A. Field, A.C. Steere, B.T. Huber, et al., Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis, Science 281 (1998), 703-706.
34. R.T. Schoen, F. Meurice, C.M. Brunet, S. Cretella, D.S. Krause, J.E. Craft, et al., Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease, J Infect Dis 172(5) (Nov 1995), 1324-1329.
35. G.S. Habicht, L.I. Katona and J.L. Benach, Cytokines and the pathogenesis of neuroborreliosis: Borrelia burgdorferi induces glioma cells to secrete interleukin-6, J Infect Dis 164(3) (Sep 1991), 568-574.
36. A.R. Pachner, K. Amemiya, E. Delaney, T. O'Neil, C.A.N. Hughes and W.F. Zhang, Interleukin-6 is expressed at high levels in the CNS in Lyme neuroborreliosis, Neurology 49 (1997), 147-152.
37. K. Kurtenbach, A. Dizij, P. Voet, P. Hauser and M.M. Simon, Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies, Vaccine 15(15) (Oct 1997), 1670-1674.
38. R.M. Wooten, V.R. Modur, T.M. McIntyre and J.J. Weis, Borrelia burgdorferi outer membrane protein A induces nuclear translocation of nuclear factor-kappa B and inflammatory activation in human endothelial cells, J Immunol 157(10) (15 Nov 1996), 4584-4590.
39. M.Weller, A. Stevens, N. Sommer, H.Wiethölter and J. Dichgans, Cerebrospinal fluid interleukins, immunoglobulins and fibronectin in neuroborreliosis, Arch Neurol 48 (1991), 837-841.
40. D. Keller, F.T. Koster, D.H. Marks, P. Hosbach, L.F. Erdile, J.P. Mays et al., Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine, JAMA 271(22) (1994), 1764-1768.
41. L.H. Sigal, J.M. Zahradnik, P. Lavin, S.J. Patella, G. Bryant, R. Haselby, et al.,Avaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant outer-surface protein a Lyme disease vaccine study consortium, N Engl J Med 339(4) (23 July 1998), 216-222.
42. A.C. Steere, V.K. Sikand, F. Meurice, D.L. Parenti, E. Fikrig, R.T. Schoen, et al., Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer surface lipoprotein A with adjuvant, NEJM 339(4) (1998), 209-215.
43. D.H. Marks, P. Hosbach, F. Koster, G.Wormser, G. Bryant, J. Gwaltney, et al., Clinical studies in humans of outer surface protein A vaccine for LD. Abstract of presentation at VI International Conference on Lyme Borreliosis, Bologna, Italy, June 19, 1994.
44. D.H. Marks, P. Hosbach and C.K. Meschievity, Design issues for clinical trials of vaccine for Lyme disease, Presented at Symposium on the Therapy and Prophylaxis for Lyme Borreliosis, Portoroz, Slovenia, 13-16 May 95.